Sylvie Négrier

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2014 · 439 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial

Sylvie Négrier, David Pérol, Alain Ravaud et al. · Journal of Clinical Oncology · 2005 · 89 citations

Medicine, Immunology, Oncology +17

Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients

Marie‐Paule Sablin, Linda Bouaita, Corinne Balleyguier et al. · Journal of Clinical Oncology · 2007 · 75 citations

Medicine, Oncology, Pharmacotherapy +15

Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients

Y. Bécouarn, Érick Gamelin, Bruno Coudert et al. · Journal of Clinical Oncology · 2001 · 61 citations

Medicine, Oncology, Pharmacology +17

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

B. Escudier, Sylvie Négrier, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2010 · 52 citations

Medicine, Oncology, Pharmacology +15